New York State Common Retirement Fund Acquires 39,934 Shares of Progyny, Inc. (NASDAQ:PGNY)

New York State Common Retirement Fund raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 18.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 256,344 shares of the company's stock after purchasing an additional 39,934 shares during the period. New York State Common Retirement Fund owned 0.27% of Progyny worth $9,531,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Cetera Trust Company N.A bought a new position in Progyny in the fourth quarter worth approximately $183,000. Handelsbanken Fonder AB raised its position in Progyny by 40.0% in the fourth quarter. Handelsbanken Fonder AB now owns 14,000 shares of the company's stock worth $521,000 after acquiring an additional 4,000 shares during the period. Kornitzer Capital Management Inc. KS raised its position in Progyny by 29.7% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 686,064 shares of the company's stock worth $25,508,000 after acquiring an additional 156,910 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Progyny by 44.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,150 shares of the company's stock worth $675,000 after acquiring an additional 5,620 shares during the period. Finally, Strs Ohio raised its position in Progyny by 85.3% in the fourth quarter. Strs Ohio now owns 18,900 shares of the company's stock worth $702,000 after acquiring an additional 8,700 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

Wall Street Analyst Weigh In

PGNY has been the topic of several recent analyst reports. Barclays initiated coverage on shares of Progyny in a research report on Wednesday, January 3rd. They set an "overweight" rating and a $48.00 price objective on the stock. SVB Leerink initiated coverage on shares of Progyny in a research report on Monday, February 26th. They set an "outperform" rating and a $49.00 price objective on the stock. Truist Financial restated a "buy" rating and set a $46.00 price objective on shares of Progyny in a research report on Wednesday, April 17th. KeyCorp decreased their price objective on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 28th. Finally, Leerink Partnrs restated an "outperform" rating on shares of Progyny in a research report on Monday, February 26th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $48.30.

Progyny Stock Performance

NASDAQ:PGNY traded down $0.22 during midday trading on Thursday, reaching $32.07. 889,784 shares of the stock traded hands, compared to its average volume of 781,846. The stock has a market capitalization of $3.08 billion, a PE ratio of 51.73, a price-to-earnings-growth ratio of 1.33 and a beta of 1.51. Progyny, Inc. has a 12-month low of $29.44 and a 12-month high of $44.95. The business has a 50-day moving average of $35.35 and a two-hundred day moving average of $35.61.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business's quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.03 earnings per share. Research analysts anticipate that Progyny, Inc. will post 0.7 earnings per share for the current year.

Insider Activity at Progyny

In other news, President Michael E. Sturmer sold 2,260 shares of the firm's stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total value of $90,400.00. Following the transaction, the president now directly owns 158,532 shares of the company's stock, valued at $6,341,280. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Chairman David J. Schlanger sold 1,000 shares of Progyny stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the completion of the transaction, the chairman now owns 83,631 shares in the company, valued at $3,137,835.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Michael E. Sturmer sold 2,260 shares of Progyny stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total transaction of $90,400.00. Following the completion of the transaction, the president now owns 158,532 shares of the company's stock, valued at approximately $6,341,280. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,515 shares of company stock worth $4,570,131. 12.30% of the stock is owned by company insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.